The division will encompass not only DSM’s own PUFA portfolio but also Martek’s algal DHA omega-3 and ARA omega-6 ingredients.
DSM Nutritional Products (Parsippany, NJ) has created a new division, Nutritional Lipids. Since DSM acquired Martek Biosciences (Columbia, MD) earlier this year, the division will encompass not only DSM’s own polyunsaturated fatty acid (PUFA) portfolio but also Martek’s algal docosahexaenoic acid (DHA) omega-3 and arachidonic acid (ARA) omega-6 ingredients. According to DSM, the umbrella of offerings makes it the world’s “leading innovator and supplier in this category.”
“The nutritional lipids category of health and nutrition ingredients is science-based, fast growing, and in an early stage of development, with significant growth opportunities,” the company stated in a press release.
Peter A Nitze, who joined Martek in 2005 and was COO at the time of its acquisition by DSM, will lead the new Nutritional Lipids division as president. Steve Dubin, Martek’s CEO at the time of its acquisition, will be taking on a new role at DSM, which is yet to be announced. David Abramson, Martek’s president at the time of acquisition, is now senior executive advisor for DSM Nutritional Products.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.